Industrials Autos Equity - China



Brilliance Auto (1114 HK)

Hold: Largely in line results; conservative outlook statement

- ► FY14 NPAT +60.1%YoY to Rmb5,403m, 3%/5% higher than our forecasts/consensus
- ▶ Company targets BMW Brilliance (BBA) sales volume to increase 10%YoY in 2015e
- ▶ Establish Hold rating with fair value TP of HKD15.5 based on 11.1x 2015e PE

Largely in-line contribution from BBA. The share of income of BBA rose 61.2%YoY, to Rmb11.1bn, in line with our forecast of Rmb11.0bn. The slightly better than expected results were driven by the less than expected loss for the mini-bus business (LBIT of Rmb320m versus HSBCe of 420m in 2014).

Conservative sales target in 2015e. The sales growth target for BBA is 10%YoY in 2015e. Although the management commented that this is a very conservative target and sees upside risks to this number, we believe this showed the pressure on the sales growth in a weak product cycle. We forecast sales volume to grow by 13%YoY in 2015e but see pressure on pricing as the model continues to age in 2015.

Don't expect immediate FX benefits. Management commented that BMW Brilliance employs rolling hedging strategy for its FX exposure. 90% of the 2015 EUR exposure was hedged earlier therefore they expect limited FX benefits for the JV in 2015. Although the company does not disclose the durations of the hedge, we believe we would only see potential benefits from FX starting from 3Q15 (as EUR began to depreciate rapidly in 3Q14). From a pure FX perspective the JV would benefit from the FX in 2016 and this could be the upside risks to our 2016e forecast, but it is not sure whether BMW will be able to capture some of the FX benefits from the JV through charging higher prices for the components/services.

Establish Hold rating with fair value TP of HKD15.5. We raised our earnings forecast for Brilliance by 2%/4% in 2015e/16e. We establish a Hold rating with fair value TP of HKD15.5 based on ROE-based target 11.1x 2015e PE. Previously, under our old model, our TP was HKD15.2. We think BMW Brilliance would face rising competition from rivals such as Beijing Benz and FAW Audi in 2015/16 but it is at least partially reflected at the current valuation. However we believe that Brilliance's slowdown in growth would be quicker than market expectation and see limited positive catalysts ahead.

Source: HSBC

Index^	HSCEI
Index level	11,969
RIC	1114.HK
Bloomberg	1114 HK

Source: HSBC

Enterprise value (CNYm) 37904 Free float (%) Market cap (USDm) 9,330 Market cap (HKDm) 72,371

Hold Target price (HKD) 15.50 Share price (HKD) 14.40 Upside/Downside (%) 7.6 2014 a 2015 e 2016 e HSBC EPS 1 07 1.14 1.40 HSBC PE 10.8 10.2 8.2 **Performance 1M** 3M 12M Absolute (%) 43 4 -5.3

16.1

27 March 2015

Carson Ng*

Relative[^] (%)

Analyst

The Hongkong and Shanghai Banking **Corporation Limited** +852 2996 6625 carsonksng@hsbc.com.hk

Mike Yip'

Associate

The Hongkong and Shanghai Banking **Corporation Limited** +852 2996 6942 mike.h.y.yip@hsbc.com.hk

View HSBC Global Research at: http://www.research.hsbc.com

*Employed by a non-US affiliate of HSBC Securities (USA) Inc, and is not registered/qualified pursuant to FINRA regulations

Issuer of report: The Hongkong and Shanghai Banking Corporation Limited

Disclaimer & **Disclosures**

This report must be read with the disclosures and the analyst certifications in the Disclosure appendix, and with the Disclaimer, which forms part of it



Financials & valuation

Financial statements						
Year to	12/2014a	12/2015e	12/2016e	12/2017e		
Profit & loss summary (CN)	Ym)					
Revenue	5,515	7,287	8,298	9,886		
EBITDA	-181	-158	17	-52		
Depreciation & amortisation	-139	-289	-291	-293		
Operating profit/EBIT	-320	-447	-273	-345		
Net interest	-103	-106	-89	-83		
PBT	5,343	5,631	6,977	8,040		
HSBC PBT	5,343	5,631	6,977	8,040		
Taxation	-43	-17	-29	-34		
Net profit	5,403	5,734	7,068	8,126		
HSBC net profit	5,403	5,734	7,068	8,126		
Cash flow summary (CNYn	1)					
Cash flow from operations	345	-176	151	408		
Capex	-806	-322	-323	-324		
Cash flow from investment	661	1,474	1,593	1,942		
Dividends	-553	-631	-778	-894		
Change in net debt	-572	-682	-966	-1,456		
FCF equity	-36	-455	-161	95		
Balance sheet summary (C	CNYm)					
Intangible fixed assets	996	985	974	963		
Tangible fixed assets	3,060	3,104	3,147	3,189		
Current assets	6,345	7,444	8,847	11,026		
Cash & others	2,526	3,207	4,174	5,629		
Total assets	23,207	28,727	35,586	43,999		
Operating liabilities	5,888	6,302	7,002	8,313		
Gross debt	1,365	1,365	1,365	1,365		
Net debt	-1,161	-1,842	-2,809	-4,264		
Shareholders funds	16,931	22,157	28,437	35,658		
Invested capital	1,986	2,023	1,792	1,235		

Ratio, growth and per share analysis						
Year to	12/2014a	12/2015e	12/2016e	12/2017e		
Y-o-y % change						
Revenue	-9.6	32.1	13.9	19.1		
PBT	60.1	5.4	23.9	15.2		
HSBC EPS	59.5	6.1	23.3	15.0		
Ratios (%)						
Revenue/IC (x)	2.7	3.6	4.3	6.5		
ROIC	-15.5	-22.2	-14.3	-22.7		
ROE	36.1	29.3	27.9	25.4		
ROA	25.9	22.2	22.1	20.5		
EBITDA margin	-3.3	-2.2	0.2	-0.5		
Operating profit margin	-5.8	-6.1	-3.3	-3.5		
Net debt/equity	-7.3	-8.7	-10.3	-12.4		
Net debt/EBITDA (x)	6.4	11.7	-162.5	81.5		
Per share data (CNY)						
EPS reported (fully diluted)	1.07	1.14	1.40	1.61		
HSBC EPS (fully diluted)	1.07	1.14	1.40	1.61		
DPS	0.11	0.13	0.15	0.18		
Book value	3.37	4.41	5.66	7.10		

Valuation data					
Year to	12/2014a	12/2015e	12/2016e	12/2017e	
PE*	10.8	10.2	8.2	7.2	
P/Book value	3.4	2.6	2.0	1.6	
Dividend yield (%)	1.0	1.1	1.3	1.5	

Note: * = Based on HSBC EPS (fully diluted)



Note: price at close of 25 Mar 2015



FY14 results highlights

- ► FY14 NPAT +60.1%YoY to Rmb5,403m, 3%/5% higher than our forecasts/consensus
- Company targets BMW Brilliance (BBA) sales volume to increase 10%YoY in 2015e
- ► Establish Hold rating with fair value TP of HKD15.5 based on 11.1x 2015e PE

Sales target

BMW Brilliance

- ▶ Brilliance targets sales growth of 10% for BMW Brilliance in 2015. Management commented that the target is conservative and see potential upside.
- ▶ We are more positive on the volume growth and forecast sales volume to grow by 13%YoY to 316k units

Mini-bus business

▶ The company sets a target of 28% growth for its domestic brand mini-van business in 2015, driven by the launch of new Huasong 7 MPV. Management targets to sell 20k units of the MPV in 2015 and believe the model could achieve total sales of 160-180k units during its 7-year model cycle.

While we are impressed with the performance of the BMW N20 engine which would be equipped on Huasong 7, we are more conservative on the sales volume of this brand new model and forecast sales volume to be 16k units in 2015e.

Volume growth guidance by company for 2015 and our forecast					
(units)	2014	Company guidance for 2015	HSBC 2015e		
BMW Brilliance	278,529	306,382	315,730		
YoY%		10%	13.4%		
Brilliance mini-van	77,710	99,469	92,376		
YoY%		28%	18.9%		

Source: Company data, HSBC estimates

3




New model launches schedule of BMW Brilliance

New product launching schedule of BMW Brilliance and domestically produced German premium brands					
	2014	2015e	2016e	2017e	2018e
BMW		2 Series Active Tourer, C, N/Oct-15 3 Series, D, F/Oct-15	X1, SUV-C. S/Mid-16	2 Series sedan, B/C, N/2017 X3, SUV-D, N/2017 5 Series, E, S/2017	3 Series, D, N/2018
Audi	A3, C, N/1H14 A3 sedan, C, N/2H14	A6, E, F/2015	A4, D, S/2016	Q2, SUV-B, N/2017 Q5, SUV-D, N/2017	
Mercedes	C-Class LWB, D, S/Sep-14	GLA, SUV-C, N/Mar-15 GLC, SUV-D, S/4Q15 C Class, D, S/2015	CLA, C, N/2016 E-Class, E, S/2016		

Source: Company data, HSBC estimates, IHS Auto

Localisation and FX exposure

- ▶ BBA established a rolling hedging strategy for its FX exposure on estimated procurement amount in Eur each year. It has already hedged 90% of its 2015 FX exposure and expects minimum benefit from EUR depreciation this year.
- Management commented that if the downtrend of EUR against Rmb continues in the long run, BBA should have cost benefit from procurement but the effect would not be immediate.
- Localisation ratio would increase upon the completion of the engine production plant. As localisation increases, the impact from FX fluctuation would be reduced gradually.







Capex and R&D expenses

- ▶ The 3rd phase of the Tiexi plant is under construction. In addition to the current generation of 3 series, the plant would product models based on the front wheel drive UKL platform including X1 and 2 series.
- ▶ Total capacity of Tiexi plant would be 400k units per annum and that of Dadong plant would be 200k per annum in medium term. The next generation of X3 would be produced in Dadong plant in 2017.
- ▶ The JV incurred Rmb9bn of capex in 2014 and plan to spend Rmb11bn of capex in 2015. This would be funded by internal cash flow.
- ▶ Depreciation of BBA in 2014 was Rmb1.8bn and expected to be Rmb2.3bn in 2015.
- R&D expenses in 2014 were Rmb1.6bn, budget in 2015 is about Rmb1.5bn.


Further comments on subsidies to dealers


- ▶ BMW Brilliance and BMW China provided subsidies for their dealers in 2014 as some of them encountered negative gross margin on new car sales.
- ▶ Management commented that the subsidies were within the company's budget and did not have extra negative impact on the margin.
- ▶ We believe the booking of the subsidies would be spread in 2014 and 2015.






















FY14 results review

FY14 results summary									
						HSBCe		Cons	Cons vs
(Rmb m)	1H14	2H14	2014	2013	YoY%	2014e	Var%	2014	actual
Revenue	2,496	3,019	5,515	6,103	-9.6%	5,448	1.2%	6,005	-8.2%
Cost of sales	(2,278)	(2,674)	(4,952)	(5,417)	-8.6%	(4,964)	-0.2%	(5,397)	-8.2%
Gross profit	218	345	562	687	-18.1%	485	16.0%	608	-7.5%
GP Margin %	8.7%	11.4%	10.2%	11.2%	-9.3%	8.9%		10.1%	
Other net income	27	77	104	96	8.3%	50	108.4%		
Selling expenses	(230)	(355)	(585)	(608)	-3.8%	(572)	2.3%		
Administrative expenses	(188)	(214)	(402)	(399)	0.5%	(383)	4.9%		
EBIT	(173)	(147)	(320)	(225)	42.2%	(420)	-23.8%		
EBIT margin %	-6.9%	-4.9%	-5.8%	-3.7%		-7.7%			
Interest income	23	30	54	47	14.4%	42	26.6%		
Finance costs, net	(77)	(80)	(156)	(139)	12.8%	(150)	4.0%		
Share of results of:	` '	` '	, ,	, ,		. ,			
Associates	122	107	229	206	11.0%	242	-5.5%		
Jointly controlled entities	3,689	1,848	5,537	3,448	60.6%	5,464	1.3%		
Profit before tax	3,585	1,758	5,343	3,338	60.1%	5,179	3.2%	5,139	4.0%
Income tax credit (expense)	(5)	(38)	(43)	(8)	412.7%	(16)	171.0%		
Net profits after tax	3,579	1,720	5,300	3,329	59.2%	5,163	2.7%		
Equity holders of the Company	3,628	1,776	5,403	3,374	60.1%	5,243	3.1%	5,146	5.0%
Non-controlling interests	(48)	(55)	(103)	(58)	78.9%	(80)	29.3%		

Source: Company data, HSBC estimates, Bloomberg consensus

FY14 results of BMW Brilliance (whole entity basis)						
(Rmb m)	2014	2013	YoY%	HSBCe	Var %	
Revenue	94,545	73,173	29.2%	94,772	-0.2%	
Pre-tax profit	14,778	9,222	60.2%	15,105	-2.2%	
Pre-tax margin %	15.6%	12.6%				
Net profit	11,072	6,871	61.2%	10,929	1.3%	
Net margin %	11.7%	9.4%		11.5%		
ASP	339,445	353,954	-4.1%	340,238	-0.2%	
Sales volume						
-5 series	93.679	60.954	53.7%			
-3 series	138,287	123,463	12.0%			
-X1	46.563	22.312	108.7%			
Total	278,529	206,729	34.7%			

Source: Company data, HSBC estimates



Earnings revision

Earnings revision							
	2014		2015e			2016e	
(RMB m)	Announced	Revised	Old	Chg%	Revised	Old	Chg%
Revenue Cost of sales Gross profit GP Margin %	5,515 (4,952) 562 10.2%	7,287 (6,340) 947 13.0%	6,041 (5,437) 604 10.0%	20.6% 16.6% 56.8%	8,298 (7,054) 1,245 15.0%	6,469 (5,692) 776 12.0%	28.3% 23.9% 60.4%
Other net income Selling expenses Administrative expenses EBIT EBIT margin %	104 (585) (402) (320) -5.8%	100 (874) (619) (447) -6.1%	50 (665) (514) (524) -8.7%	100.0% 31.6% 20.6% -14.8%	100 (913) (705) (273) -3.3%	50 (712) (550) (435) -6.7%	100.0% 28.3% 28.3% -37.2%
Interest income Finance costs, net Share of results of: Associates	54 (156) 230	51 (156) 269	42 (143) 279	20.0% 8.8% -3.5%	64 (153) 283	55 (148) 279	15.8% 3.8% 1.3%
Jointly controlled entities	5,536	5,914	5,898	0.3%	7,057	7,004	0.8%
Profit (Loss) before tax Income tax credit (expense) Profit (Loss) for the year	5,343 (43) 5,300	5,631 (17) 5,614	5,552 (19) 5,533	1.4% -11.7% 1.5%	6,977 (29) 6,948	6,755 (16) 6,739	3.3% 83.3% 3.1%
Attributable to: Equity holders of the Company Non-controlling interests	5,403 (103)	5,734 (120)	5,613 (80)	2.2% 50.0%	7,068 (120)	6,819 (80)	3.7% 50.0%

Source: Company data, HSBC estimates

Assumptions change for BMW Brilliance					
	Revised			Old	
	2014	2015e	2016e	2015e	2016e
Sales volume					
Total sales (units)	278,529	315,730	382,611	315,748	377,632
YoY%	34.7%	13.4%	21.2%	13.4%	19.6%
By models					
- 3 series	93,679	111,478	120,396	111,485	120,404
- 5 series	138,287	153,499	168,848	153,501	168,851
- X1	46,563	50,754	58,367	50,762	58,377
- Others	-	· -	35,000	-	30,000
Financials (RMB m)					
Revenue	94,545	106,013	125,485	106,018	124,389
YoY%	29.2%	12.1%	18.4%	11.9%	17.3%
Operating profits	14,778	15,770	18,819	15,728	18,677
Operating margin (%)	15.6%	14.9%	15.0%	14.8%	15.0%
Net profits after tax	11,072	11,827	14,114	11,796	14,007
Net profit margin (%)	11.7%	11.2%	11.2%	11.1%	11.3%

Source: Company data, HSBC estimates



Valuation and risks

- ▶ Target PE based on ROE and long-term growth
- ▶ Formula for calculating our ROE-based PE:

$$PE = (ROE - g) \div (ROE \times [COE - g])$$

Fig 11: Key assumptions		
ROE 2015e	25.9%	
Cost of equity Rf Equity risk premium Equity beta	11.0% 3.5% 6.5% 1.15 3.0%	

Source: HSBC estimates

- ▶ We use 3-year historical beta of 1.15 according to Bloomberg. Our growth and COE assumptions remain unchanged.
- Applying our 2015e ROE assumption of 25.9% (previously 24.6%) to the above formula, we derive a fair ROE-based PE multiple of 11.1x (previously 10.9x) for Brilliance.
- Applying our 2015e diluted EPS estimate of RMB1.14 (previously RMB1.11) to our target PE, our fair value target price is HKD15.5 (previously, under our old ratings model, it was HKD15.2)
- We established a Hold rating versus the previous Neutral rating.

Key downside risks: slowdown in premium segment growth, lower-than-expected margin expansion, and market share losses to major competitors.

Key upside risks: Lower than expected procurement costs benefiting from depreciating Euro against Rmb.



Disclosure appendix

Analyst Certification

The following analyst(s), economist(s), and/or strategist(s) who is(are) primarily responsible for this report, certifies(y) that the opinion(s) on the subject security(ies) or issuer(s) and/or any other views or forecasts expressed herein accurately reflect their personal view(s) and that no part of their compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report: Carson Ng and Mike Yip

Important disclosures

Equities: Stock ratings and basis for financial analysis

HSBC believes an investor's decision to buy or sell a stock should depend on individual circumstances such as the investor's existing holdings, risk tolerance and other considerations and that investors utilise various disciplines and investment horizons when making investment decisions. Ratings should not be used or relied on in isolation as investment advice. Different securities firms use a variety of ratings terms as well as different rating systems to describe their recommendations and therefore investors should carefully read the definitions of the ratings used in each research report. Further, investors should carefully read the entire research report and not infer its contents from the rating because research reports contain more complete information concerning the analysts' views and the basis for the rating.

From 23rd March 2015 HSBC has assigned ratings on the following basis:

The target price is based on the analyst's assessment of the stock's actual current value, although we expect it to take six to 12 months for the market price to reflect this. When the target price is more than 20% above the current share price, the stock will be classified as a Buy; when it is between 5% and 20% above the current share price, the stock may be classified as a Buy or a Hold; when it is between 5% below and 5% above the current share price, the stock will be classified as a Hold; when it is between 5% and 20% below the current share price, the stock may be classified as a Hold or a Reduce; and when it is more than 20% below the current share price, the stock will be classified as a Reduce.

Our ratings are re-calibrated against these bands at the time of any 'material change' (initiation or resumption of coverage, change in target price or estimates).

Upside/Downside is the percentage difference between the target price and the share price.

Prior to this date, HSBC's rating structure was applied on the following basis:

For each stock we set a required rate of return calculated from the cost of equity for that stock's domestic or, as appropriate, regional market established by our strategy team. The target price for a stock represented the value the analyst expected the stock to reach over our performance horizon. The performance horizon was 12 months. For a stock to be classified as Overweight, the potential return, which equals the percentage difference between the current share price and the target price, including the forecast dividend yield when indicated, had to exceed the required return by at least 5 percentage points over the succeeding 12 months (or 10 percentage points for a stock classified as Volatile*). For a stock to be classified as Underweight, the stock was expected to underperform its required return by at least 5 percentage points over the succeeding 12 months (or 10 percentage points for a stock classified as Volatile*). Stocks between these bands were classified as Neutral.

*A stock was classified as volatile if its historical volatility had exceeded 40%, if the stock had been listed for less than 12 months (unless it was in an industry or sector where volatility is low) or if the analyst expected significant volatility. However, stocks which we did not consider volatile may in fact also have behaved in such a way. Historical volatility was defined as the past month's average of the daily 365-day moving average volatilities. In order to avoid misleadingly frequent changes in rating, however, volatility had to move 2.5 percentage points past the 40% benchmark in either direction for a stock's status to change.




Rating distribution for long-term investment opportunities

As of 26 March 2015, the distribution of all ratings published is as follows:

Buy	41%	(30% of these provided with Investment Banking Services)
Hold	39%	(27% of these provided with Investment Banking Services)
Sell	20%	(20% of these provided with Investment Banking Services)

For the purposes of the distribution above the following mapping structure is used during the transition from the previous to current rating models: under our previous model, Overweight = Buy, Neutral = Hold and Underweight = Sell; under our current model Buy = Buy, Hold = Hold and Reduce = Sell. For rating definitions under both models, please see "Stock ratings and basis for financial analysis" above.

Share price and rating changes for long-term investment opportunities



Recommendation & price target history				
From	То	Date		
Overweight (V)	Overweight	03 March 2014		
Overweight	Neutral	01 February 2015		
Target Price	Value	Date		
Price 1	11.20	28 March 2012		
Price 2	8.20	26 July 2012		
Price 3	9.70	29 August 2012		
Price 4	13.20	17 February 2013		
Price 5	13.50	27 March 2013		
Price 6	13.60	11 August 2013		
Price 7	14.70	13 August 2013		
Price 8	17.10	03 March 2014		
Price 9	15.90	27 March 2014		
Price 10	18.30	18 July 2014		
Price 11	15.20	01 February 2015		
Source: HSBC	13.20	OTT EDILIARY 20		



HSBC & Analyst disclosures

Disclosure checklist					
Company	Ticker	Recent price	Price Date	Disclosure	
BRILLIANCE AUTO	1114.HK	14.24	26-Mar-2015	6,7	

Source: HSBC

- 1 HSBC has managed or co-managed a public offering of securities for this company within the past 12 months.
- 2 HSBC expects to receive or intends to seek compensation for investment banking services from this company in the next 3 months.
- 3 At the time of publication of this report, HSBC Securities (USA) Inc. is a Market Maker in securities issued by this company.
- 4 As of 28 February 2015 HSBC beneficially owned 1% or more of a class of common equity securities of this company.
- As of 31 January 2015, this company was a client of HSBC or had during the preceding 12 month period been a client of and/or paid compensation to HSBC in respect of investment banking services.
- As of 31 January 2015, this company was a client of HSBC or had during the preceding 12 month period been a client of and/or paid compensation to HSBC in respect of non-investment banking securities-related services.
- As of 31 January 2015, this company was a client of HSBC or had during the preceding 12 month period been a client of and/or paid compensation to HSBC in respect of non-securities services.
- 8 A covering analyst/s has received compensation from this company in the past 12 months.
- 9 A covering analyst/s or a member of his/her household has a financial interest in the securities of this company, as detailed below.
- 10 A covering analyst/s or a member of his/her household is an officer, director or supervisory board member of this company, as detailed below.
- At the time of publication of this report, HSBC is a non-US Market Maker in securities issued by this company and/or in securities in respect of this company

HSBC and its affiliates will from time to time sell to and buy from customers the securities/instruments (including derivatives) of companies covered in HSBC Research on a principal or agency basis.

Analysts, economists, and strategists are paid in part by reference to the profitability of HSBC which includes investment banking revenues.

Whether, or in what time frame, an update of this analysis will be published is not determined in advance.

For disclosures in respect of any company mentioned in this report, please see the most recently published report on that company available at www.hsbcnet.com/research.

Additional disclosures

- 1 This report is dated as at 27 March 2015.
- 2 All market data included in this report are dated as at close 25 March 2015, unless otherwise indicated in the report.
- HSBC has procedures in place to identify and manage any potential conflicts of interest that arise in connection with its Research business. HSBC's analysts and its other staff who are involved in the preparation and dissemination of Research operate and have a management reporting line independent of HSBC's Investment Banking business. Information Barrier procedures are in place between the Investment Banking and Research businesses to ensure that any confidential and/or price sensitive information is handled in an appropriate manner.



Disclaimer

* Legal entities as at 30 May 2014

'UAE' HSBC Bank Middle East Limited, Dubai; 'HK' The Hongkong and Shanghai Banking Corporation Limited, Hong Kong; 'TW' HSBC Securities (Taiwan) Corporation Limited; 'CA' HSBC Bank Canada, Toronto; HSBC Bank, Paris Branch; HSBC France; 'DE' HSBC Trinkaus & Burkhardt AG, Düsseldorf; 000 HSBC Bank (RR), Moscow; 'IN' HSBC Securities and Capital Markets (India) Private Limited, Mumbai; 'JP' HSBC Securities (Japan) Limited, Tokyo; 'EG' HSBC Securities Egypt SAE, Cairo; 'CN' HSBC Investment Bank Asia Limited, Beijing Representative Office; The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch; The Hongkong and Shanghai Banking Corporation Limited, Seoul Securities Branch; The Hongkong and Shanghai Banking Corporation Limited, Seoul Branch; HSBC Securities (South Africa) (Pty) Ltd, Johannesburg; HSBC Bank plc, London, Madrid, Milan, Stockholm, Tel Aviv; 'US' HSBC Securities (USA) Inc, New York; HSBC Yatirim Menkul Degerler AS, Istanbul; HSBC México, SA, Institución de Banca Múltiple, Grupo Financiero HSBC; HSBC Bank Brasil SA — Banco Múltiplo; HSBC Bank Australia Limited; HSBC Bank Argentina SA; HSBC Saudi Arabia Limited; The Hongkong and Shanghai Banking Corporation Limited, New Zealand Branch incorporated in Hong Kong SAR; The Hongkong and Shanghai Banking Corporation Limited, Bangkok Branch

Issuer of report The Hongkong and Shanghai Banking Corporation Limited

Level 19, 1 Queen's Road Central

Hong Kong SAR

Telephone: +852 2843 9111 Fax: +852 2596 0200

Website: www.research.hsbc.com

This document has been issued by The Hongkong and Shanghai Banking Corporation Limited ("HSBC") in the conduct of its Hong Kong regulated business for the information of its institutional and professional investor (as defined by Securities and Future Ordinance (Chapter 571)) customers; it is not intended for and should not be distributed to retail customers in Hong Kong. The Hongkong and Shanghai Banking Corporation Limited is regulated by the Hong Kong Monetary Authority. All enquires by recipients in Hong Kong must be directed to your HSBC contact in Hong Kong. If it is received by a customer of an affiliate of HSBC, its provision to the recipient is subject to the terms of business in place between the recipient and such affiliate. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. HSBC has based this document on information obtained from sources it believes to be reliable but which it has not independently verified; HSBC makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of the Research Division of HSBC only and are subject to change without notice. HSBC and its affiliates and/or their officers, directors and employees may have positions in any securities mentioned in this document (or in any related investment) and may from time to time add to or dispose of any such securities (or investment). HSBC and its affiliates may act as market maker or have assumed an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell those companies

HSBC Securities (USA) Inc. accepts responsibility for the content of this research report prepared by its non-US foreign affiliate. All U.S. persons receiving and/or accessing this report and wishing to effect transactions in any security discussed herein should do so with HSBC Securities (USA) Inc. in the United States and not with its non-US foreign affiliate, the issuer of this report.

In the UK this report may only be distributed to persons of a kind described in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. The protections afforded by the UK regulatory regime are available only to those dealing with a representative of HSBC Bank plc in the UK. In Singapore, this publication is distributed by The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch for the general information of institutional investors or other persons specified in Sections 274 and 304 of the Securities and Futures Act (Chapter 289) ("SFA") and accredited investors and other persons in accordance with the conditions specified in Sections 275 and 305 of the SFA. This publication is not a prospectus as defined in the SFA. It may not be further distributed in whole or in part for any purpose. The Hongkong and Shanghai Banking Corporation Limited Singapore Branch is regulated by the Monetary Authority of Singapore. Recipients in Singapore should contact a "Hongkong and Shanghai Banking Corporation Limited, Singapore Branch" representative in respect of any matters arising from, or in connection with this report. In Australia, this publication has been distributed by The Hongkong and Shanghai Banking Corporation Limited (ABN 65 117 925 970, AFSL 301737) for the general information of its "wholesale" customers (as defined in the Corporations Act 2001). Where distributed to retail customers, this research is distributed by HSBC Bank Australia Limited (AFSL No. 232595). These respective entities make no representations that the products or services mentioned in this document are available to persons in Australia or are necessarily suitable for any particular person or appropriate in accordance with local law. No consideration has been given to the particular investment objectives, financial situation or particular needs of any recipient. This publication is distributed in New Zealand by The Hongkong and Shanghai Banking Corporation Limited, New Zealand Branch incorporat

In Japan, this publication has been distributed by HSBC Securities (Japan) Limited. It may not be further distributed in whole or in part for any purpose. In Korea, this publication is distributed by The Hongkong and Shanghai Banking Corporation Limited, Seoul Securities Branch ("HBAP SLS") for the general information of professional investors specified in Article 9 of the Financial Investment Services and Capital Markets Act ("FSCMA"). This publication is not a prospectus as defined in the FSCMA. It may not be further distributed in whole or in part for any purpose. HBAP SLS is regulated by the Financial Services Commission and the Financial Supervisory Service of Korea.

In Canada, this document has been distributed by HSBC Bank Canada and/or its affiliates. Where this document contains market updates/overviews, or similar materials (collectively deemed "Commentary" in Canada although other affiliate jurisdictions may term "Commentary" as either "macro-research" or "research"), the Commentary is not an offer to sell, or a solicitation of an offer to sell or subscribe for, any financial product or instrument (including, without limitation, any currencies, securities, commodities or other financial instruments).

© Copyright 2015, The Hongkong and Shanghai Banking Corporation Limited, ALL RIGHTS RESERVED. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, on any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of The Hongkong and Shanghai Banking Corporation Limited. MICA (P) 157/06/2014, MICA (P) 136/02/2015 and MICA (P) 041/01/2015



Global Industrials Research Team

Industrials

Colin Gibson

Global Sector Head, Industrials

colin.gibson@hsbcib.com +44 20 7991 6592

Sean McLoughlin

Analyst +44 20 7991 3464 sean.mcloughlin@hsbcib.com

Michael Hagmann Analyst

+44 20 7991 2405 michael.hagmann@hsbcib.com

Mark Webb

Analyst

+852 2996 6574 markwebb@hsbc.com.hk

Parash Jain

Analyst

+852 2996 6717 parashjain@hsbc.com.hk

Shishir Singh Analyst

+852 2822 4292

shishirkumarsingh@hsbc.com.hk

Stephen Wan Analyst

+852 2996 6566 stephenwan@hsbc.com.hk

Thomas Zhu, CFA Analyst

+852 2822 4325

thomasjzhu@hsbc.com.hk

Carrie Liu

Analyst

+8862 6631 2864 carriecfliu@hsbc.com.tw

Brian Cho

Head of Research, Korea

+822 3706 8750 briancho@kr.hsbc.com

Paul Choi Analyst

+822 3706 8758 paulchoi@kr.hsbc.com

Yeon Lee

Analyst

+822 3706 8778 yeonlee@kr.hsbc.com

Sinyoung Park

+822 3706 8770 sinyoungpark@kr.hsbc.com

Incheol Yu Associate

+822 3706 8756 incheolyu@kr.hsbc.com

Thilan Wickramasinghe

+65 6658 0609 thilanw@hsbc.com.sg

Kristy Lee

Analyst

+65 6658 0616 kristy.zx.lee@hsbc.com.sg

Puneet Gulati

+91 22 2268 1235 puneetgulati@hsbc.co.in

Joerg-Andre Finke

+49 211 910 3722 joerg-andre.finke@hsbc.de

Richard Schramm

+49 211 910 2837 richard.schramm@hsbc.de

Juergen Siebrecht

Analyst

+49 211 910 3350 juergen.siebrecht@hsbc.de

Autos

Horst Schneider

+49 211 910 3285 horst.schneider@hsbc.de

Carson Ng

Analyst

+852 2822 4397 carsonksng@hsbc.com.hk

Mike Yip

Associate

+852 2996 6942 mike.h.y.yip@hsbc.com.hk

Yogesh Aggarwal

Analyst

+91 22 2268 1246 vogeshaggarwal@hsbc.co.in Transportation

Andrew Lobbenberg

Analyst

+44 20 7991 6816 andrew.lobbenberg@hsbcib.com

Joe Thomas Analyst

+44 20 7992 3618 joe.thomas@hsbcib.com

Wei Sim Analyst

+852 2996 6602 weisim@hsbc.com.hk

Shishir Singh

+852 2822 4292 shishirkumarsingh@hsbc.com.hk

Achal Kumar

Analyst +91 80 3001 3722 achalkumar@hsbc.co.in

Rajani Khetan Analyst

+852 3941 0830 rajanikhetan@hsbc.com.hk

Aric Hui

Associate

+852 2822 3165 ariccshui@hsbc.com.hk

Construction & Engineering

Pierre Bosset

Head of French Research

pierre.bosset@hsbc.com +33 1 56 52 43 10

Tarun Bhatnagar

Analyst

+65 6658 0614 tarunbhatnagar@hsbc.com.sg

John Fraser-Andrews

Analyst

+44 20 7991 6732 john.fraser-andrews@hsbcib.com

Jeffrey Davis Analvst

+44 207 991 6837 ieffrev1.davis@hsbcib.com

Ivan Enriquez +52 55 5721 2397

Anderson Chow

Analyst +852 2996 6669 andersonchow@hsbc.com.hk

Lesley Liu

Analyst +852 2822 4524

lesleylliu@hsbc.com.hk

ivan.enriquez@hsbc.com.mx

Raj Sinha

Analyst +971 4423 6932 raj.sinha@hsbc.com

Levent Bayar

Analyst

+90 212 376 46 17 leventbayar@hsbc.com.tr

Ashutosh Narkar

+91 22 2268 1474 ashutoshnarkar@hsbc.co.in

Tobias Loskamp

Analyst +49 211 910 2828 tobias.loskamp@hsbc.de

Specialist Sales

Rod Turnbull +44 20 7991 5363

rod.turnbull@hsbcib.com

Oliver Magis

+49 21 1910 4402 oliver.magis@hsbc.de

Rillal Ismail

+44 20 7991 5362 billal.ismail@hsbcib.com

Jean Gael Tabet

+44 20 7991 5342 jeangael.tabet@hsbcib.com